The Present and Future Trend of Monoclonal Antibody
DOI:
https://doi.org/10.54097/cy800q90Keywords:
Monoclonal antibody, cancer therapy, Pertuzumab, Trastuzumab.Abstract
Over the past three decades, the realm of monoclonal antibodies has witnessed a remarkable metamorphosis. Initially conceptualized and utilized as mere scientific instruments, these antibodies have now evolved into potent therapeutic agents, revolutionizing the landscape of modern medicine. The United States and Europe, being at the forefront of medical advancements, have embraced this transformation, with nearly 30 therapeutic monoclonal antibodies currently available in their markets. These antibodies, tailored to target specific antigens, offer a precision in treatment that was previously unattainable. This review delves into the intricate journey of monoclonal antibodies, tracing their origins, their initial applications in research, and their eventual rise as therapeutic giants. Furthermore, the paper sheds light on the challenges faced in their development, the breakthroughs that propelled their success, and the potential future innovations that could further harness their capabilities. As standing on the cusp of medical breakthroughs, understanding the past and potential future trajectories of monoclonal antibodies becomes paramount.
Downloads
References
Sandra MS, Mythili S, Erika H. Targeting HER2-positive-breast-cancer: advances and future directions. Nat Rev Drug Discov, 2022, 22 (2): 101–126.
Buss NA, Henderson SJ, McFarlane M, et al. Monoclonal antibody therapeutics: history and future. Curr Opin Pharmacol, 2012, 12 (5): 615-622.
Slamon DJ. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 2001, 344: 783–792.
Slamon DJ, Eiermann W, Robert NJ, et al. Ten year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC→T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+ early breast cancer. Cancer Res, 2016, 76: S5–04.
Swain SM, Miles D, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol, 2020, 21 (4): 519-530.
Piccart M, Procter M, Fumagalli D, et al. Adjuvant Pertuzumab and Trastuzumab in Early HER2-positive-breast-cancer in the APHINITY Trial: 6 Years' Follow-Up. J Clin Oncol, 2021, 39 (13): 1448-1457.
Murthy RK, Loi S, Okines A, et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N Engl J Med, 2020, 382 (7): 597-609.
Diéras V, Miles D, Verma S, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol, 2017, 18 (6): 732-742.
Krop IE, Kim SB, Martin AG, et al. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol, 2017, 18 (6): 743-754.
Uppal H, Doudement E, Mahapatra K, et al. Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1). Clin Cancer Res, 2015, 21 (1): 123-133.
Modi S, Saura C, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-positive-breast-cancer. N Engl J Med, 2020, 382 (7): 610-621.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
